← All trials
NCT01937806
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2013
- Primary completion
- Jul 1, 2015
- Completion date
- Jan 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 188
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- IlDong Pharmaceutical Co LtdLead sponsor
- Inje UniversityOverall official - principal investigator
- Korea UniversityOverall official - principal investigator
- Seoul National UniversityOverall official - principal investigator
- Ajou UniversityOverall official - principal investigator
- Hallym UniversityOverall official - principal investigator
- Hanyang UniversityOverall official - principal investigator
- Inha UniversityOverall official - principal investigator
- Chungnam National UniversityOverall official - principal investigator
- Wonju Christian HospitalOverall official - principal investigator
- Catholic University of KoreaOverall official - principal investigator
- Yonsei UniversityOverall official - principal investigator
- University of UlsanOverall official - principal investigator
- Kyungpook UniversityOverall official - principal investigator
- Soonchunhyang UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.